Clinical, Microbiological, and Economic Benefit of a Change in Antibiotic Prophylaxis for Cardiac Surgery
- 1 July 2002
- journal article
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 23 (7), 402-404
- https://doi.org/10.1086/502074
Abstract
Vancomycin and rifampicin replaced cephazolin as antibiotic prophylaxis for coronary artery bypass surgery at our institution. Following this intervention, there was a significant decrease (P< .001) in the surgical-site infection rate from 10.5 (95% confidence interval, 8.2 to 13.3) to 4.9 (95% confidence interval, 3.2 to 7.1) infections per 100 procedures. An estimated $576,655 (Australian) was saved between two 12-month periods.Keywords
This publication has 8 references indexed in Scilit:
- Cost of surgical site infections following coronary artery bypass surgeryAnz Journal of Surgery, 2001
- RISK FACTORS FOR SURGICAL WOUND INFECTION AND BACTERAEMIA FOLLOWING CORONARY ARTERY BYPASS SURGERYAnz Journal of Surgery, 2000
- Comparison of Vancomycin and Cefuroxime for Infection Prophylaxis in Coronary Artery Bypass SurgeryInfection Control & Hospital Epidemiology, 1998
- Risk Factors Associated with Vancomycin-Resistant Enterococcus faecium Infection or Colonization in 145 Matched Case Patients and Control PatientsClinical Infectious Diseases, 1996
- Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operationsThe Journal of Thoracic and Cardiovascular Surgery, 1992
- CDC Definitions of Nosocomial Surgical Site Infections, 1992: A Modification of CDC Definitions of Surgical Wound InfectionsInfection Control & Hospital Epidemiology, 1992
- Antibiotic prophylaxis for cardiothoracic operationsThe Journal of Thoracic and Cardiovascular Surgery, 1992
- Rifampin blood and tissue levels in patients undergoing cardiac valve surgeryAntimicrobial Agents and Chemotherapy, 1982